Viz.ai

Viz.ai pioneered the use of artificial intelligence to accelerate time-to-treatment for life-threatening conditions, connecting care teams in real time when minutes determine outcomes. Founded in 2016 and headquartered in San Francisco, California, the company built its platform around the insight that detecting a large vessel occlusion stroke on a CT scan and alerting the right specialist within seconds, rather than hours, can preserve neurological function at scale.

AI-Powered Care Coordination Platform

The Viz platform analyses medical imaging as it comes off the scanner, applies FDA-cleared AI algorithms to detect abnormalities, and simultaneously routes automated alerts to on-call specialists via a dedicated care-team communication app. What began in stroke expanded into a broad portfolio covering pulmonary embolism, aortic disease, cardiac conditions, and oncology pathways. The company markets this as a care coordination network rather than a standalone diagnostic tool, emphasising workflow integration alongside detection.

Scale & Hospital Network

Viz.ai operates across hundreds of hospitals in the United States and has expanded internationally. Its network model means that as more sites connect, the routing intelligence spans entire health systems and transfer networks, enabling spoke hospitals to reach comprehensive stroke centres rapidly. The company raised substantial venture funding before moving towards broader commercial expansion, and its devices have received multiple FDA 510(k) clearances across different clinical indications.

Customers include academic medical centres, integrated delivery networks, and community hospitals seeking to standardise time-sensitive clinical pathways without restructuring radiology or specialist staffing. The platform sits within existing PACS and EHR workflows, reducing the implementation burden.

Further information is available at viz.ai.